STARGLO 2-year follow-up: durability of responses in patients with DLBCL receiving Glofitamab-GemOx

Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Fiona Stanley Hospital & Monash University, Perth, Australia, presents the two-year follow-up of the STARGLO trial (NCT04408638), a registrational trial assessing glofitamab in combination with gemcitabine and oxaliplatin (Glofitamab-GemOx) versus rituximab in combination with gemcitabine and oxaliplatin (R-GemOx) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Gregory notes the encouraging efficacy of Glofitamab-GemOx, highlighting that a high durability of responses has been observed. This suggests that Glofitamab-GemOx may offer a cure for a proportion of patients without the need for cellular therapy, addressing a significant unmet clinical need in this space. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.